Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic ...

Corcept Therapeutics said on Monday its experimental drug in combination with chemotherapy helped delay progression of a type of ovarian cancer in a late-stage trial. The company's shares surged about ...

Corcept is studying relacorilant in a variety of serious disorders in addition to ovarian cancer, including endogenous hypercortisolism (Cushing's syndrome) and prostate cancer. The views and ...

Corcept Therapeutics (CORT) announced the start of BELLA, a Phase 2 trial of relacorilant plus nab-paclitaxel and bevacizumab evaluating ...

The BELLA phase 2 clinical trial of relacorilant plus nab-paclitaxel and Avastin among patients with platinum-resistant ...

Corcept is studying relacorilant in a variety of serious disorders in addition to ovarian cancer, including endogenous hypercortisolism (Cushing’s syndrome) and prostate cancer. Relacorilant is ...

Corcept Therapeutics Incorporated (NASDAQ ... for patients with platinum-resistant ovarian cancer. The trial is an open-label study with an enrollment target of 90 women across approximately ...

Luveltamab tazevibulin demonstrated activity in an ongoing phase 2/3 trial of patients with FRα-positive, platinum-resistant ovarian cancer.

Corcept Therapeutics Incorporated (NASDAQ ... evaluating efficacy and safety in patients with platinum-resistant ovarian cancer.

In other recent news, Corcept Therapeutics has reported positive results from its pivotal Phase 3 ROSELLA trial, which evaluated relacorilant in combination with nab-paclitaxel for patients with ...